← Back to screener

Zymeworks Inc. ZYME

Rank #2228 · Nasdaq · $2.1B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
28.4
P/E
-17.6
P/B
4.24
ROE
-24.1%
Op. Margin
-181.6%
Debt Ratio
25%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -17.6x, P/B 4.24x. Ranks in the top 70% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -24.1%. Ranks in the top 88% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 25%. Ranks in the top 15% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 81.6% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2022$0.0B$-0.2B$-0.2B$0.2B-481.357
2023$0.0B$-0.2B$-0.2B$0.4B-808.238
2024$0.4B$0.1B$0.1B$0.2B31.647
2025$0.1B$-0.1B$-0.1B$0.5B-181.625

← See the full screener